Hemoglobinopathies
19 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Benserazide Only Product for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Benserazide Only Product for beta-thalassemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BMS-986470 for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BMS-986470 + Famotidine + PANTOPRAZOLE for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BMS-986470 + Placebo for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) for anemia, sickle cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Crizanlizumab for anemia, sickle cell | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for anemia, sickle cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EDIT-301 for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exagamglogene autotemcel for anemia, sickle cell | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Exagamglogene autotemcel for beta-thalassemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Exerenibart for beta-thalassemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GVHD prophylaxis regimen + RIC regimen for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxycarbamide for anemia, sickle cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Iloprost for vaso-occlusive crises | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for hemoglobinopathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Established Dose from prior study, NCT03810196 for hemoglobinopathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for hemoglobinopathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation for anemia, sickle cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |